AI-generated summary
This randomized, single-blind trial compared intravenous red laser irradiation (660 nm) of blood with a sham procedure in 28 people with HIV, all receiving antiretroviral therapy. The authors report that both groups had reduced viral load, with no statistically significant differences between groups in any outcome. The study was stopped early during an interim analysis, and the authors conclude the laser showed no clinical or statistical superiority as an adjuvant therapy.
- Participants
- 28
- Who or what was studied
- People living with HIV/AIDS receiving antiretroviral therapy
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The trial was stopped prematurely at interim analysis and enrolled only 28 participants, with no statistically significant between-group differences reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objective
To evaluate the effectiveness of intravenous laser irradiation of blood in reducing viral load and increasing LT-CD4+ and LT-CD8+ in people living with HIV/AIDS.
Method
Randomized, controlled, parallel, single-blind clinical trial. Twenty-eight participants were allocated to the intervention (ILIB n = 15) and control (CTRL n = 13) groups. The ILIB group received irradiation with red laser (660 nm), applied to the radial artery (30 minutes/day for 20 days), with a total energy of 180 J. The CTRL group received a sham intervention (without light emission). Viral load and LT-CD4+ and LT-CD8+ counts were assessed at the end.
Results
Both groups showed a reduction in viral load (ILIB: -1.7 log; CTRL: -2.3 log). In the ILIB group, 61.5% of participants achieved an undetectable viral load (p = 0.449). There was no increase in CD4+ LT count (p = 0.287), but a non-significant reduction in CD8+ LT count was observed in the ILIB group (p = 0.173). There were no statistically significant differences between groups for any outcome (p > 0.17). The study was stopped prematurely during the interim analysis.
Conclusion
ILIB, as an adjuvant therapy to ART, did not show clinical or statistical superiority in the immunological and virological parameters evaluated. BRAZILIAN REGISTRY OF CLINICAL TRIALS (REBEC): RBR-7j9rv5d (https://ensaiosclinicos.gov.br/trial/10848).
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Total energy
- 180 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.